← All trials
NCT05075122
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 2, 2021
- Primary completion
- Aug 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Oct 12, 2021
- Last posted
- Oct 12, 2021
- Enrollment
- 75
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Martin Luther UniversityLead sponsor
- Martin Luther UniversityReponsible party - principal investigator
- Ultimovacs ASCollaborator
- Johannes Gutenburg UniversityCollaborator
- https://www.researchgate.net/profile/Axel-HinkeCCRC Cancer Clinical Research Consulting (Düsseldorf, GermanyCollaborator
- University of HalleOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.